Valuation: Sanofi

Market Cap 84.84B 95.51B 79.14B 72.09B 136B 9,192B 137B 959B 372B 4,688B 359B 351B 15,069B P/E 2026 *
11.3x
P/E 2027 * 9.81x
Enterprise Value 96.74B 109B 90.24B 82.2B 155B 10,482B 157B 1,094B 424B 5,346B 409B 400B 17,184B EV / Sales 2026 *
2.03x
EV / Sales 2027 * 1.85x
Free-Float
88.34%
Yield 2026 *
6.01%
Yield 2027 * 6.35%
1 day-3.91%
1 week-2.26%
Current month-2.20%
1 month-8.31%
3 months-7.61%
6 months-15.62%
Current year-14.59%
1 week 18.2
Extreme 18.2
18.95
1 month 18.2
Extreme 18.2
19.46
Current year 18.2
Extreme 18.2
22.02
1 year 18.2
Extreme 18.2
22.57
3 years 18.2
Extreme 18.2
22.57
5 years 18.2
Extreme 18.2
22.57
10 years 18.2
Extreme 18.2
22.57
Manager TitleAgeSince
Chief Executive Officer 65 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer - 2026-08-31
Director TitleAgeSince
Director/Board Member 61 2019-04-29
Director/Board Member 56 2020-04-27
Director/Board Member 65 2020-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-3.91%-2.26% - - 95.48B
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -1.08%-3.39%+26.07%+58.90% 410.8B
Weighted average by Cap. -0.68%-3.33%+29.07%+71.15%

Financials

2026 *2027 *
Net sales 47.66B 53.66B 44.46B 40.5B 76.47B 5,164B 77.14B 539B 209B 2,634B 201B 197B 8,466B 50.62B 56.99B 47.22B 43.02B 81.22B 5,485B 81.93B 572B 222B 2,798B 214B 209B 8,992B
Net income 7.48B 8.42B 6.98B 6.36B 12.01B 811B 12.11B 84.61B 32.79B 414B 31.63B 30.93B 1,329B 8.9B 10.02B 8.31B 7.57B 14.29B 965B 14.41B 101B 39.01B 492B 37.63B 36.8B 1,582B
Net Debt 11.91B 13.41B 11.11B 10.12B 19.1B 1,290B 19.27B 135B 52.17B 658B 50.33B 49.22B 2,115B 8.61B 9.7B 8.03B 7.32B 13.82B 933B 13.94B 97.38B 37.74B 476B 36.4B 35.6B 1,530B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Date Price Change Volume
26-10-02 $18.20 -3.91% 800
26-10-01 $18.94 +1.77% 203
26-09-28 $18.61 -0.05% 1,000
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
70.81EUR
Average target price
94.06EUR
Spread / Average Target
+32.83%

Quarterly revenue - Rate of surprise